Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Perion Network Ltd. , a leader in advanced technology solving for the complexities of modern advertising, announced today the filing of its annual report on Form 20-F for the fiscal year ended ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's ...

Clinical-stage oncology company Prescient Therapeutics Ltd has opened the first clinical site for its Phase 2a study of ...

HC Wainwright issued their FY2029 earnings estimates for Erasca in a report issued on Friday, March 21st. HC Wainwright ...

The fifth and latest scheme to assist working families and renters to transition into homeownership has been launched. Limerick City and County Council has announced the launch of its initiative under ...

StockNews.com upgraded shares of Verastem (NASDAQ:VSTM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Monday. A number of other equities analysts have ...